Halozyme Therapeutics Inc. (1HALO)
MTA
95.98
-4.27 (-4.26%)
Closed
Oct 2, 2026
Day's Range
88.7295.98
52 wk Range
48.73103.00
Financial Statements - 1HALO - Halozyme Therapeutics Inc.
Revenue
1.39B▲ 62.1%
Net Income
316.88M▼ 15.9%Net Margin 22.7%
EBITDA
890.64M▲ 65.8%
Free Cash Flow
356.81M▼ 10.2%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Sales | 1.39B | 861.66M |
| Cost of Goods | 228.77M | 135.29M |
| Gross Profit | 1.16B | 726.37M |
 Operating Expense | - | - |
| Operating Income | 802.59M | 468.01M |
| Non-Operating Interest | - | - |
| Other Income Expense | -317.59M | 20.15M |
| Pre Tax Income | 466.87M | 472.81M |
| Income Tax | 149.98M | 95.93M |
| Net Income | 316.88M | 376.88M |
| EPS Basic | 2.64 | 3.5 |
| EPS Diluted | 2.56 | 3.43 |
| Basic Shares Outstanding | 119.84M | 107.63M |
| Diluted Shares Outstanding | 119.84M | 107.63M |
| Ebit | 485M | 488.17M |
| Ebitda | 890.64M | 537.02M |
| Net Income Continuous Operations | 316.88M | 376.88M |
| Minority Interests | - | - |
| Preferred Stock Dividends | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
